Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.
Carlton M Kelly, Mathieu Fradet, Catherine M Bostian et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label clinical trial investigated the effects of a single 25-mg dose of psilocybin on anxiety, quality of life, and functioning in veterans with treatment-resistant depression. Results showed a 59% reduction in anxiety severity (GAD-7) at Week 3, with sustained improvements observed through 12 months, although many effects correlated with improvements in depressive symptoms.
Key findings
- GAD-7 scores showed a 59% reduction from baseline at Week 3.
- Quality of life (Q-LES-Q-SF) increased by 24% at Week 3.
- Functional impairment (WSAS) improved by 46% at Week 3.
- Unadjusted PCL-5 reductions were observed at all timepoints.
Why it matters
The findings suggest that psilocybin-assisted therapy may offer significant benefits for veterans with treatment-resistant depression, particularly in reducing anxiety and improving quality of life, which are critical components of overall mental health.
What to keep in mind
This study is limited by its small sample size and open-label design.